We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Section: AI

Assessing an AI Chatbot for HIV Prevention in Malaysia: Insights and Usability

MedXY Editorial Team•Oct 2, 2025•AI
AI chatbotHIV prevention

Study Background and Disease Burden

Malaysia faces a complex and growing HIV epidemic that has notably shifted from needle sharing among drug users to sexual transmission, particularly affecting men who have sex with men (MSM). According to the Malaysian Ministry of Health, MSM account for a significant proportion of new HIV diagnoses, emphasizing the critical need for targeted interventions. In response, our research team developed a web-based artificial intelligence (AI) chatbot, positioned to facilitate HIV awareness and testing among this vulnerable population. The chatbot was launched on MYHIV365, designed to be a user-friendly resource promoting HIV testing and healthcare access.

Objective

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Open language-specific specialty feeds and department pages.

Dapivirine Vaginal Ring and Oral PrEP Confirmed Safe for Use During Second Trimester: Insights from the DELIVER TrialThe Phase 3b DELIVER trial confirms that both the dapivirine vaginal ring and oral PrEP are safe and well-tolerated when initiated in the second trimester of pregnancy, showing no product-related serious adverse events and high rates of terFeb 14, 2026Infant Safety After In-Utero Exposure to Dapivirine Ring or Oral PrEP: 12‑Month Findings from MTN‑042/DELIVERIn a randomized phase 3b trial of pregnant women using the dapivirine vaginal ring or daily oral TDF/FTC for HIV prevention, 12‑month infant follow‑up showed no product‑related serious or grade 3+ adverse events and no HIV transmissions, suNov 13, 2025Enhancing Depression Care in College Students: AI Chatbots with Social Cues Show Superior EffectivenessA 16-week randomized trial demonstrates that AI chatbots with high-social-cue design significantly reduce depression and anxiety symptoms in college students compared to text-only chatbots, improving adherence, satisfaction, and therapeuticOct 5, 2025FDA Approves Lenacapavir: A Twice-Yearly Injectable PrEP Transforming HIV Prevention
Loading comments...
MedXY briefing

Get the free newsletter

Evidence-led clinical news, trends, and analysis—delivered to your inbox.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
Lenacapavir (Yeztugo) becomes the first FDA-approved, twice-yearly injectable PrEP, offering robust long-acting HIV prevention and addressing key adherence barriers.
Sep 30, 2025